Sort   by:  
 Page size 
UnknownCOVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.
Not available
S-EPMC8444788 | biostudies-literature
UnknownTreatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.
Not available
S-EPMC10076530 | biostudies-literature
UnknownClinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Not available
S-EPMC7426107 | biostudies-literature
UnknownTubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways.
Not available
S-EPMC6584054 | biostudies-literature
UnknownRetrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
Not available
S-EPMC8613139 | biostudies-literature
UnknownHigh BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors.
Not available
S-EPMC12713232 | biostudies-literature
UnknownChronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey.
Not available
S-EPMC7301058 | biostudies-literature
UnknownImatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.
Not available
S-EPMC5346773 | biostudies-literature
UnknownNovel genes and sex differences in COVID-19 severity.
Not available
S-EPMC9652109 | biostudies-literature
Sort   by:  
 Page size